3QG2

Plasmodium falciparum DHFR-TS qradruple mutant (N51I+C59R+S108N+I164L, V1/S) pyrimethamine complex

3QG2 の概要

• エントリーDOI: 10.2210/pdb3qg2/pdb
• 関連するPDBエントリー: 3QFX 3QGT 3RG9
• 分子名称: Bifunctional dihydrofolate reductase-thymidylate synthase, 5-(4-CHLORO-PHENYL)-6-ETHYL-PYRIMIDINE-2,4-DIAMINE, NADPH DIHYDRO-NICOTINAMIDE-ADENINE-DINUCLEOTIDE PHOSPHATE, ... (5 entities in total)
• 機能のキーワード: pyrimethamine, antifolate resistance, plasmodium falciparum, dihydrofolate reductase, oxidoreductase, transferase, transferase-inhibitor complex, transferase/inhibitor
• 由来する生物種: Plasmodium falciparum
• タンパク質・核酸の鎖数: 2
• 化学式量合計: 146420.89

構造登録者

Vanichtanankul, J.,Yuvaniyama, J.,Taweechai, S.,Chitnumsub, P.,Kamchonwongpaisan, S.,Yuthavong, Y. (登録日: 2011-01-24, 公開日: 2011-06-29, 最終更新日: 2023-11-01)

主引用文献

Vanichtanankul, J.,Taweechai, S.,Yuvaniyama, J.,Vilaivan, T.,Chitnumsub, P.,Kamchonwongpaisan, S.,Yuthavong, Y.
Trypanosomal dihydrofolate reductase reveals natural antifolate resistance
Acs Chem.Biol., 6:905-911, 2011

PubMed Abstract: Dihydrofolate reductase (DHFR) is a potential drug target for Trypanosoma brucei, a human parasite, which is the causative agent for African sleeping sickness. No drug is available against this target, since none of the classical antifolates such as pyrimethamine (PYR), cycloguanil, or trimethoprim are effective as selective inhibitors of T. brucei DHFR (TbDHFR). In order to design effective drugs that target TbDHFR, co-crystal structures with bound antifolates were studied. On comparison with malarial Plasmodium falciparum DHFR (PfDHFR), the co-crystal structures of wild-type TbDHFR reveal greater structural similarities to a mutant PfDHFR causing antifolate resistance than the wild-type enzyme. TbDHFR imposes steric hindrance for rigid inhibitors like PYR around Thr86, which is equivalent to Ser108Asn of the malarial enzymes. In addition, a missing residue on TbDHFR active-site loop together with the presence of Ile51 widens its active site even further than the structural effect of Asn51Ile, which is observed in PfDHFR structures. The structural similarities are paralleled by the similarly poor affinities of the trypanosomal enzyme for rigid inhibitors. Mutations of TbDHFR at Thr86 resulted in 10-fold enhancement or 7-fold reduction in the rigid inhibitors affinities for Thr86Ser or Thr86Asn, respectively. The co-crystal structure of TbDHFR with a flexible antifolate WR99210 suggests that its greater affinity result from its ability to avoid such Thr86 clash and occupy the widened binding space similarly to what is observed in the PfDHFR structures. Natural resistance to antifolates of TbDHFR can therefore be explained, and potential antifolate chemotherapy of trypanosomiasis should be possible taking this into account.

PubMed: 21650210
DOI: 10.1021/cb200124r

実験手法

X-RAY DIFFRACTION (2.3 Å)